spacer
home > ict > winter 2019 > strategic success
PUBLICATIONS
International Clinical Trials

Strategic Success

ICT: With the addendum to the ICH E6 (R2) Guideline for Good Clinical Practice (GCP), the GCP has seen its first significant update in over 20 years. What is the new guideline and how does it impact clinical trial design?

Patrick Hughes: The ICH GCP Guidance Integrated Addendum provides a unified standard for the EU, Japan, the US, Canada, and Switzerland. The updated ICH E6 (R2) guidelines have been introduced to encourage the implementation of improved and more efficient approaches to clinical trial design, conduct, oversight, recording, and reporting, while continuing to ensure human subject protection and reliability of trial results. Far from being considered a hurdle to overcome, the ICH E6 (R2) should be a positive step forward and an exciting opportunity for more efficient clinical R&D, with significantly better outcomes.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Patrick Hughes is the Chief Commercial Officer at CluePoints. He holds a marketing degree from Newcastle University, UK, and a postgraduate marketing diploma in B2B marketing strategy from the Kellogg School of Management, US. Responsible for leading global sales, product, marketing, operational, and technical teams throughout his career, Patrick is a Senior Executive with over eighteen years of international commercial experience within life sciences, healthcare, and telecommunications.
spacer
Patrick Hughes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Owen Mumford Launches New 2-Step Single-Use Auto-Injector Platform Aidaptus®

OXFORD, England, 22nd September - Owen Mumford Pharmaceutical Services, a division of Owen Mumford Ltd. has launched its new Aidaptus® auto-injector platform following successful completion of development. Aidaptus is a 2-step, spring-powered, single use auto-injector with a versatile design that accommodates both 1mL and 2.25 mL prefilled glass syringes in the same base device. It also features stopper sensing technology with a self-adjusting plunger that automatically adapts to the individual stopper positions and different fill volumes in each syringe, with no change parts required. The auto-injector is available with two different spring strengths to accommodate a variety of drug viscosities.
More info >>

White Papers

Wrap Around Label - A Lot of Content in a Small Space

Faubel & Co. Nachfolger GmbH

One of the world’s largest contract research organizations for the planning and conducting of clinical trials was faced with the challenge of accommodating many different national languages on an inhaler. The inhaler was then to be distributed in 47 countries. Due to the impressive quality and reliable collaboration, the organization commissioned Faubel with finding the optimal labeling solution for the inhaler.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement